| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Avelumab |
| Brand | Bavencio® |
| Indication | For the treatment of adults with metastatic Merkel Cell Carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 17/10/2017 |
| Rapid review completed | 21/11/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 22/11/2017 |
| Pre-submission consultation with Applicant | 11/12/2017 |
| Full submission received from Applicant | 16/03/2018 |
| Preliminary review sent to Applicant | 12/07/2018 |
| NCPE assessment re-commenced | 10/08/2018 |
| Factual accuracy sent to Applicant | 06/09/2018 |
| NCPE assessment re-commenced | 20/09/2018 |
| NCPE assessment completed | 08/10/2018 |
| NCPE assessment outcome | The NCPE recommends that avelumab (Bavencio®) for the treatment of metastatic Merkel Cell Carcinoma not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. |
The HSE has approved reimbursement “approval is restricted to second line” following confidential price negotiations May 2019.